➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Last Updated: June 14, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for AGN-201904

Email this page to a colleague

« Back to Dashboard

What is the drug development status for AGN-201904?

AGN-201904 is an investigational drug.

There have been 50 clinical trials for AGN-201904. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2014.

The most common disease conditions in clinical trials are Presbyopia, Ocular Hypertension, and Glaucoma. The leading clinical trial sponsors are Allergan, Naurex, Inc, an affiliate of Allergan plc, and Vitae Pharmaceuticals Inc., an Allergan affiliate.

There are two US patents protecting this investigational drug and forty-three international patents.

Recent Clinical Trials for AGN-201904
A Study to Assess the Impact and Adverse Events of Topical Eyedrops of AGN-190584 on Night-driving Performance in Participants, 40 to 55 Years of AgeAllerganPhase 3
AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular HypertensionAllerganPhase 1/Phase 2
Phase 1/2 Study of AGN-241622 in Healthy Participants and Participants With PresbyopiaAllerganPhase 1/Phase 2

See all AGN-201904 clinical trials

Clinical Trial Summary for AGN-201904

Top disease conditions for AGN-201904
Top clinical trial sponsors for AGN-201904

See all AGN-201904 clinical trials

US Patents for AGN-201904

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AGN-201904   Get Started Free Prodrugs of proton pump inhibitors Winston Pharmaceuticals, Inc. (Newport Beach, CA) The United States of America as represented by the Department of Veteran Affairs (Washington, DC) N/A (Oakland, CA) The Reagents of the University of California (N/A)   Get Started Free
AGN-201904   Get Started Free Process for preparing isomerically pure prodrugs of proton pump inhibitors Allergan, Inc. (Irvine, CA)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AGN-201904

Drugname Country Document Number Estimated Expiration Related US Patent
AGN-201904 Argentina AR042513 2022-07-19   Get Started Free
AGN-201904 Austria AT323695 2022-07-19   Get Started Free
AGN-201904 Australia AU2003259154 2022-07-19   Get Started Free
AGN-201904 Brazil BR0312802 2022-07-19   Get Started Free
AGN-201904 Canada CA2492718 2022-07-19   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.